Your account is not claimed yet. You can sign up with ORCID to claim your account.

Andrew J Lloyd (A J Lloyd, Andrew Lloyd)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 22

Top Venues

PharmacoEconomics

Journal of patient-reported outcomes

Journal of medical economics

PharmacoEconomics - open

This page only lists publications with an associated author ORCID identifier.

Publications

Hayley M de Freitas, David Danese, Lena Hubig, Andrew J Lloyd, Stephen Lombardelli
Estimating health state utilities in primary hyperoxaluria type 1: a valuation study. Journal of medical economics (2023)
Hayley M de Freitas, David Danese, Lena Hubig, Andrew J Lloyd, Stephen Lombardelli
Estimating health state utilities in primary hyperoxaluria type 1: a valuation study. Journal of medical economics 26 (1) (2023)
Irene Santi, Andrew J Lloyd, Claudia E Hastedt, Matthijs M Versteegh
Societal Utilities for Cognitive Impairment in Schizophrenia: Developing a Preference-Based Scoring Algorithm Based on the Schizophrenia Cognition Rating Scale. Advances in therapy (2023)
Mara Violato, Jack Pollard, Andrew J Lloyd, Laurence S J Roope, Raymond Duch, Matias Fuentes Becerra, Philip M Clarke
The COVID-19 pandemic and health-related quality of life across 13 high- and low-middle-income countries: A cross-sectional analysis. PLoS medicine 20 (4) (2023)
Elena Nicod, Andrew J Lloyd, Thomas Morel, Michela Meregaglia, Sheela Upadhyaya, Amanda Whittal, Karen M Facey, Michael F Drummond
Improving Interpretation of Evidence Relating to Quality of Life in Health Technology Assessments of Rare Disease Treatments. The patient (2022)
G Biolcati, S Hanneken, E I Minder, N J Neumann, J H P Wilson, P J Wolgen, D J Wright, Andrew J Lloyd
Correction to: Validation of a novel patient reported tool to assess the impact of treatment in erythropoietic protoporphyria: the EPP-QoL. Journal of patient-reported outcomes 5 (1) (2021)
Siu Hing Lo, Ksenija Gorni, C Simone Sutherland, Yasmina Martí, Andrew J Lloyd, Noman Paracha
Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom. PharmacoEconomics (2021)
G Biolcati, S Hanneken, E I Minder, N J Neumann, J H P Wilson, P J Wolgen, D J Wright, Andrew J Lloyd
Validation of a novel patient reported tool to assess the impact of treatment in erythropoietic protoporphyria: the EPP-QoL. Journal of patient-reported outcomes 5 (1) (2021)
Christine Blome, Jill Carlton, Christoph Heesen, Mathieu F Janssen, Andrew J Lloyd, Marina Otten, John E Brazier
How to measure fluctuating impairments in people with MS: development of an ambulatory assessment version of the EQ-5D-5L in an exploratory study. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 30 (7) (2021)
Beenish Nafees, Andrew J Lloyd, Sarah Dewilde
Estimating health state utilities in hemophagocytic lymphohistiocytosis. Journal of patient-reported outcomes 5 (1) (2021)
Janine Verstraete, Andrew J Lloyd, Jennifer Jelsma
Performance of the Toddler and Infant (TANDI) Health-Related Quality of Life Instrument in 3-4-Year-Old Children. Children (Basel, Switzerland) 8 (10) (2021)
Siu Hing Lo, Rohini Sharma, Charlotte E Costentin, Daniel Aggio, Suki Shergill, Fabien Colaone, Victoria K Brennan, Vincenzo A Straccia, Ion Agirrezabal, Andrew J Lloyd
Patient preferences for advanced hepatocellular carcinoma treatment: a multicountry stated preference study. Future oncology (London, England) 17 (32) (2021)
Siu Hing Lo, Claire Lawrence, Yasmina Martí, Andreia Café, Andrew J Lloyd
Patient and Caregiver Treatment Preferences in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy: A Discrete Choice Experiment Survey in Five European Countries. PharmacoEconomics 40 (Suppl 1) (2021)
Siu Hing Lo, Jade Marshall, Hanna Skrobanski, Andrew J Lloyd
Patient and Caregiver Health State Utilities in Tuberous Sclerosis Complex. PharmacoEconomics - open (2021)
Siu Hing Lo, Andrew J Lloyd, Shuayb Elkhalifa, Zlatko Sisic, Floortje E van Nooten
Time Trade-Off Utilities for Hereditary Angioedema Health and Caregiver States. PharmacoEconomics - open (2021)
Kate Williams, Daniel Aggio, Peter Chen, Katerina Anokhina, Andrew J Lloyd, Yan Wang
Utility Values Associated with Atypical Hemolytic Uremic Syndrome-Related Attributes: A Discrete Choice Experiment in Five Countries. PharmacoEconomics 39 (8) (2021)
Santiago Zuluaga-Sanchez, Megan Teynor, Christopher Knight, Robin Thompson, Thomas Lundqvist, Mats Ekelund, Annabelle Forsmark, Adrian D Vickers, Andrew J Lloyd
Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden. PharmacoEconomics 37 (6) (2020)
Jacie T Cooper, Andrew J Lloyd, Juan Jose Garcia Sanchez, Elisabeth Sörstadius, Andrew Briggs, Phil McFarlane
Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature review. Health and quality of life outcomes 18 (1) (2020)
Andrew J Lloyd, Robin Thompson, Katy Gallop, Megan Teynor
Estimation Of The Quality Of Life Benefits Associated With Treatment For Spinal Muscular Atrophy. ClinicoEconomics and outcomes research : CEOR 11 (2019)
Andrew J Lloyd, Natalia Piglowska, Thomas Ciulla, Sarah Pitluck, Scott Johnson, Marric Buessing, Thomas O'Connell
Estimation of impact of RPE65-mediated inherited retinal disease on quality of life and the potential benefits of gene therapy. The British journal of ophthalmology 103 (11) (2019)
Trevor Thompson, Andrew J Lloyd, Alain Joseph, Margaret Weiss
The Weiss Functional Impairment Rating Scale-Parent Form for assessing ADHD: evaluating diagnostic accuracy and determining optimal thresholds using ROC analysis. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 26 (7) (2017)
Catherine J Bottomley, Andrew J Lloyd, Gary Bennett, Nicholas Adlard
A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis. Journal of medical economics 20 (8) (2017)

Andrew J Lloyd.css-eqlu8i{font-size:small;padding-left:4px;} (A J Lloyd, Andrew Lloyd)

Publication Activity (10 Years)

Top Topics

Top Venues

Andrew J Lloyd (A J Lloyd, Andrew Lloyd)